Comparative effectiveness and safety of tislelizumab versus other anti–PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non–small cell lung cancer: Systematic literature review and network meta-analysis

Authors: Girard, Nicolas ^{a, ⁎}, Han, Ji-Youn ^b, Soo, Ross A. ^c, Wang, Kaijun ^d, Tang, Wenxi ^d, Nikolaidis, Georgios F. ^e, Tasoulas, Anastasios ^f, Barouma, Ifigeneia ^f, Castro, JeanPierre Coaquira ^{d, 1}, Yang, Zheyuan ^e, Chaudhary, Tanushree ^g, Zhan, Lin ^d

Source: In Lung Cancer March 2025 201

Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma

Authors: Choi, Wonyoung ^{a, b, 1}, Lee, Wonyeop ^{a, 1}, Kim, Youngwook ^{c, d}, Lee, Sang-Jin ^e, Lee, Geon Kook ^f, Park, Seung-Jin ^{g, h}, Ju, Sinyeong ⁱ, Kim, Seon-Young ^{g, h, j}, Lee, Cheolju ^{i, k}, Han, Ji-Youn ^{a, b, l, ⁎}

Source: In Lung Cancer March 2025 201

Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials

Authors: Camidge, D. Ross ^{a, ⁎}, Sugawara, Shunichi ^b, Kondo, Masashi ^c, Kim, Hye Ryun ^d, Ahn, Myung-Ju ^e, Yang, James C.H. ^f, Han, Ji-Youn ^g, Hochmair, Maximilian J. ^h, Lee, Ki Hyeong ⁱ, Delmonte, Angelo ^j, Kudou, Kentarou ^k, Asato, Takayuki ^l, Hupf, Bradley ^m, Vranceanu, Florin ^m, Fram, Robert J. ^m, Ohe, Yuichiro ⁿ, Popat, Sanjay ^o

Source: In Lung Cancer March 2025 201

Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3

Authors: Gray, Jhanelle E., Markovets, Aleksandra, Reungwetwattana, Thanyanan, Majem, Margarita, Nogami, Naoyuki, Peled, Nir, Lee, Jong-Seok, Cho, Byoung Chul, Chewaskulyong, Busayamas, John, Tom, Han, Ji-Youn, Sebastian, Martin, Todd, Alexander, Rukazenkov, Yuri, Barrett, Carl, Chmielecki, Juliann, Lee, Siow Ming, Ramalingam, Suresh S., Hartmaier, Ryan

Source: In Journal of Thoracic Oncology November 2024 19(11):1525-1538

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial

Authors: Wolf, Jürgen ^*, Hochmair, Maximilian, Han, Ji-Youn, Reguart, Noemi, Souquet, Pierre-Jean, Smit, Egbert F, Orlov, Sergey V, Vansteenkiste, Johan, Nishio, Makoto, de Jonge, Maja, Akerley, Wallace, Garon, Edward B, Groen, Harry J M, Tan, Daniel S W, Seto, Takashi, Frampton, Garrett M, Robeva, Anna, Carbini, Mariana, Le Mouhaer, Sylvie, Yovine, Alejandro, Boran, Aislyn, Bossen, Claudia, Yang, Yiqun, Ji, Lexiang, Fairchild, Lauren, Heist, Rebecca S

Source: In The Lancet Oncology October 2024 25(10):1357-1370

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Afanasyev, Sergey, Ahmed, Samreen, Alekshun, Todd, Alves, Gustavo, Anderson, Ian, Araujo, Luiz Henrique, Arkhipov, Alexander, Arora, Arvind, Bai, Jie, Begin, Paul, Belonogov, Aleksandr, Berard, Henri, Berceanu-Ion, Radu, Bernabe Caro, Reyes, Bondarenko, Igor, Bonnet, Reiner, Bosch Barrera, Joaquim, Brocca, Carlos, Bryl, Maciej, Bulotta, Alessandra, Bylicki, Olivier, Calles Blanco, Antonio, Carcereny, Enric, Carvalho, Leticia, Cebotaru, Cristina, Chaft, Jamie, Charu, Veena, Chaves, Fabio, Chen, Jun, Chen, Ke-Neng, Chen, Haiquan, Chen, Qixun, Chen, Kevin, Chiang, Chi-Lu, Chiu, Chao-Hua, Cicenas, Saulius, Ciubotaru, Elena, Ciuleanu, Tudor, Ciurescu, Ioana, Cobb, Patrick, Coetzee, Corlia, Collins, Dearbhaile, Cortinovis, Diego, Costas, Kimberly, Costin, Dan, Cronemberger, Eduardo Henrique, Cuevo, Raymund, Cuffe, Sinead, De Marchi, Pedro Rafael Martins, de Paiva Junior, Tadeu, Delmonte, Angelo, Demedts, Ingel, Deschepper, Koenraad, Dias, Josiane, Dooms, Christophe, Duchemann, Boris, Dutra, Carolina, Duvivier, Herbert, Eigendorff, Ekkehard, Ernani, Vinicius, Faehling, Martin, Faria, Luiza, Fedenko, Alexander, Fernando, Hiran, Ferrara, Roberto, Ferrari, Vittorio, Finley, Gene, Fix, Peter, Flores, Marcos, Fourie, Samuel, Franke, Fabio, Frohling, Klaus-Peter, Furqan, Muhammad, Gal, Cristian, Galamaga, Robert, Ganea, Doina, Ganti, Apar Kishor, Gao, Shugeng, Garassino, Marina, Gentzler, Ryan, Gianni, Luca, Gilli, Marina, Girard, Nicolas, Goranov, Bojidar, Gregorc, Vanesa, Greystoke, Alastair, Grisanti, Salvatore, Grohe, Christian, Guarino, Michael, Guimaraes, Jose Luiz, Guisier, Florian, Halmos, Balazs, Hammoud, Zane Taysir, Han, Ji-Youn, Hegmane, Alinta, Heng, Fook Yew, Horinouchi, Hidehito, Horio, Yoshitsugu, Hu, Jian, Huang, Hsu-Ching, Hui, Rina, Ikeda, Norihiko, Intagliata, Salvatore, Iordan, Ingrid, Jacobs, Conrad, Jain, Kirti, Jain, Sushil, Jiang, Tao, Karaseva, Nina, Kato, Terufumi, Kaywin, Paul, Kazmi, Shayma, Keresztes, Roger, Khan, Sarah, Kim, Jhingook, Kolesnik, Olena, Kolesnik, Oleksii, Kollmeier, Jens, Komiya, Takefumi, Koontz, Michael, Krasnohrud, Yuliia, Kristedja, Timothy, Kryzhanivska, Anna, Kuroda, Hiroaki, Laktionov, Konstantin, Lambrechts, Marc, Lang, Susanne, Langleben, Adrian, Lee, Se-Hoon, Lehmann, Markus, Levchenko, Evgeny, Levenko, Oleh, Li, Shanqing, Liao, Bin-Chi, Liberman, Moishe, Lima, Iane, Liu, Geoffrey, Liu-Dumlao, Theresa, Lo Russo, Giuseppe, Lou, Yan Yan, Lowczak, Anna, Luft, Alexander, Ma, Shaohua, Majem Tarruella, Margarita, Makles, Krytsyna, Martinengo, Gaston, Martinez Marti, Alex, Matias, Danielli, Mazieres, Julien, Mazilu, Laura, Mennecier, Bertrand, Migliorino, Maria Rita, Misleh, Jamal, Molina, Julian, Morbeck, Igor, Mueller, Annette, Muto, Satoshi, Nadal Alforja, Ernest, Nesterova, Alfiya, Nishio, Wataru, Niu, Jiaxin, Novello, Silvia, O'Brien, Mary, O'Day, Steven, Ogliari, Francesca, Okada, Morihito, Pang, Yong Kek, Paramonov, Viktor, Pastor, Andrea, Pawlak, Ireneusz, Piantedosi, Francovito, Pollock, Theodore, Pope, Tony, Puig, Juan, Radhi, Saba, Rao, Suman, Rathnasabapathy, Chenthilmurugan, Reck, Martin, Reinacher-Schick, Anke, Rich, Patricia, Ritgen, Mathias, Rittmeyer, Achim, Roca, Elisa, Rodriguez-Abreu, Delvys, Ruff, Paul, Rybkin, Igor, Saji, Hisashi, Sakao, Yukinori, Sangal, Ashish, Santoro, Armando, Sardenberg, Rodrigo, Savvides, Panayiotis, Scheusan, Roxana, Schiller, Joan, Schumacher, Lana, Serke, Monika, Shim, Byoung Yong, Shimizu, Junichi, Shio, Yutaka, Sibille, Anne, Siegel, Robert, Signorelli, Diego, Smagina, Maria, Sokur, Iryna, Spicer, Jonathan, Srkalovic, Gordan, Stampleman, Laura, Starodub, Alexander, Stencel, Katarzyna, Sugio, Kenji, Surmont, Veerle, Suzuki, Hiroyuki, Tabacof, Jacques, Takamochi, Kazuya, Tan, Lijie, Tanaka, Fumihiro, Tatangelo, Marcelo, Täuscher, Dagmar, Teixeira, Carlos, Thiberville, Luc, Trukhin, Dmytro, Tsai, Chen-Liang, Tsuboi, Masahiro, Ungureanu, Andrei, Ursol, Grygorii, Vanakesa, Tonu, Vansteenkiste, Johan, Varela, Mirta, Villalona-Calero, Miguel, Villaruz, Liza, Vogel, Gunther, Voitko, Nataliia, Wakelee, Heather, Wang, Qun, Wang, Wenxiang, Wang, Chin-Chou, Wang, Sarah, Wehler, Thomas, Weksler, Benny, Wermke, Martin, Wesseler, Claas, Wirtz, Hubert, Wong, Mark, Yan, Xiaolong, Yang, Yue, Yu, Kong Leong, Zasadny, Xavier, Zemaitis, Marius, Zhang, Lanjun, Zhao, Guofang, Zhao, Qing, Zhu, Yuming, Zurawski, Bogdan, Spicer, Jonathan D ^{*, *}, Garassino, Marina C ^*, Majem, Margarita, Martinengo, Gastón L, Rodríguez-Abreu, Delvys, Chaft, Jamie E, Yang, Jing, Arunachalam, Ashwini, Keller, Steven M, Samkari, Ayman

Source: In The Lancet 28 September-4 October 2024 404(10459):1240-1252

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

Authors: Solomon, Benjamin J., Dagogo-Jack, Ibiayi, Lee, Se-Hoon, Boyer, Michael J., Ramalingam, Suresh S., Carcereny, Enric, Felip, Enriqueta, Han, Ji-Youn, Hida, Toyoaki, Hughes, Brett G.M., Kim, Sang-We, Nishio, Makoto, Seto, Takashi, Okamoto, Tatsuro, Zhang, Xiaoxi, Martini, Jean-Francois, Wang, Erjian, De Beukelaer, Steven, Bauer, Todd M.

Source: In JTO Clinical and Research Reports July 2024 5(7)

Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.

Authors: Han, Ji-Youn¹ (AUTHOR) jymama@ncc.re.kr, Ahn, Myung-Ju² (AUTHOR), Lee, Ki Hyeong³ (AUTHOR), Lee, Yun-Gyoo⁴ (AUTHOR), Kim, Dong-Wan⁵ (AUTHOR), Min, Young Joo⁶ (AUTHOR), Kim, Sang-We⁷ (AUTHOR), Cho, Eun Kyung⁸ (AUTHOR), Kim, Joo-Hang⁹ (AUTHOR), Lee, Gyeong-Won¹⁰ (AUTHOR), Lee, Sung Sook¹¹ (AUTHOR), Lee, Na Mi¹² (AUTHOR), Jang, Hyun Woo¹² (AUTHOR), Han, Heewon¹² (AUTHOR), Park, Hyejoo¹² (AUTHOR), Lee, Jieon¹² (AUTHOR), Cho, Byoung Chul¹³ (AUTHOR)

Source: BMC Medicine. 10/8/2024, Vol. 22 Issue 1, p1-10. 10p.

Subject Terms: *EPIDERMAL growth factor receptors, *CIRCULATING tumor DNA, *NON-small-cell lung carcinoma, *OVERALL survival, *PROTEIN-tyrosine kinase inhibitors

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

Authors: Chul Cho, Byoung, Han, Ji-Youn, Hyeong Lee, Ki, Lee, Yun-Gyoo, Kim, Dong-Wan, Joo Min, Young, Kim, Sang-We, Kyung Cho, Eun, Kim, Joo-Hang, Lee, Gyeong-Won, Sook Lee, Sung, Lee, NaMi, Young Wang, Jang, Park, Hyejoo, Ahn, Myung-Ju

Source: In Lung Cancer April 2024 190

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic

Authors: Gray, Jhanelle E., Han, Ji-Youn, Telaranta-Keerie, Aino, Huang, Xiangning, Kohlmann, Alexander, Hodge, Rachel, Rukazenkov, Yuri, Chmielecki, Juliann, Espenschied, Carin R., Lefterova, Martina, Wu, Yi-Long, Ramalingam, Suresh S., Barrett, J. Carl, Odegaard, Justin I.

Source: In The Journal of Molecular Diagnostics January 2024 26(1):73-84

Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review

Authors: Wolf, Jürgen, Souquet, Pierre-Jean, Goto, Koichi, Cortot, Alexis, Baik, Christina, Heist, Rebecca, Kim, Tae Min, Han, Ji-Youn, Neal, Joel W., Mansfield, Aaron S., Gilloteau, Isabelle, Nwana, Ngozi, Waldron-Lynch, Maeve, Davis, Keith L., Giovannini, Monica, Awad, Mark M.

Source: In Clinical Lung Cancer November 2023 24(7):641-650

Splicing signature database development to delineate cancer pathways using literature mining and transcriptome machine learning

Authors: Lee, Kyubin, Hyung, Daejin, Cho, Soo Young, Yu, Namhee, Hong, Sewha, Kim, Jihyun, Kim, Sunshin, Han, Ji-Youn, Park, Charny

Source: In Computational and Structural Biotechnology Journal 2023 21:1978-1988

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Authors: Cho, Byoung Chul, Han, Ji-Youn, Kim, Sang-We, Lee, Ki Hyeong, Cho, Eun Kyung, Lee, Yun-Gyoo, Kim, Dong-Wan, Kim, Joo-Hang, Lee, Gyeong-Won, Lee, Jong-Seok, Shim, Byoung Yong, Kim, Jin-Soo, Chun, Sang Hoon, Lee, Sung Sook, Kim, Hye Ryun, Hong, Min Hee, Ahn, Jin Seok, Sun, Jong-Mu, Lee, Youngjoo, Lee, Dae Ho, Kang, Ji Ah, Lee, NaMi, Kwon, Mi-Jung, Espenschied, Carin, Yablonovitch, Arielle, Ahn, Myung-Ju

Source: In Journal of Thoracic Oncology April 2022 17(4):558-567

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Authors: Stahel, Rolf, Peters, Solange, Soo, Ross, Han, Ji-Youn, Früh, Martin, Provencio, Mariano, Coate, Linda, Dafni, Urania, Hiltbrunner, Anita, Ruepp, Barbara, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adriana, Giacomelli, Nino, Kammler, Rosita, Marti, Nesa, Nobs, Lionel, Pardo-Contreras, Mariana, Pfister, Rita, Piguet, Anne-Christine, Ribeli-Hofmann, Sabrina, Martinez, Virginia Rodriguez, Roux, Susanne, Sanchez-Hohl, Magdalena, Schneider, Mirjam, Schweri, Robin, Troesch, Sandra, Zigomo, Isabel, Tsourti, Zoi, Zygoura, Panagiota, Kassapian, Marie, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Fernandez, Maria, Pereira, Eva, Simona, Carolina, Tucker, Lisa, Burnes, Jillian, Barrett, Aisling, McGrillen, Meghan, Berset, Catherine, Biaggi, Christine, Reist, Martin, Rentsch, Priska, Cuffe, Sinead, Hashemi, Sayed, Nadal, Ernest, Carcereny, Enric, de Castro, Javier, Sala, Maria Angeles, Reyes, Bernabé, Pulla, Mariano Provencio, Campelo, Rosario Garcia, Massutí, Bartomeu, Garcia, Jose, Dómine, Manuel, Majem, Margarita, Sanchez, Jose Miguel, Britschgi, Christian, Pless, Miklos, Yeo, Chong Ming, Cho, Byoung Chul, Soo, R.A., Han, J.-Y., Dafni, U., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabé, R., Coate, L., Provencio Pulla, M., Garcia Campelo, R., Cuffe, S., Hashemi, S.M.S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., Sanchez-Torres, J.-M., Britschgi, C., Pless, M., Dimopoulou, G., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A., Peters, S.

Source: In Annals of Oncology February 2022 33(2):181-192

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Authors: Dziadziuszko, Rafal, Mok, Tony, Peters, Solange, Han, Ji-Youn, Alatorre-Alexander, Jorge, Leighl, Natasha, Sriuranpong, Virote, Pérol, Maurice, de Castro Junior, Gilberto, Nadal, Ernest, de Marinis, Filippo, Frontera, Osvaldo Arén, Tan, Daniel S.W., Lee, Dae Ho, Kim, Hye Ryun, Yan, Mark, Riehl, Todd, Schleifman, Erica, Paul, Sarah M., Mocci, Simonetta, Patel, Rajesh, Assaf, Zoe June, Shames, David S., Mathisen, Michael S., Gadgeel, Shirish M.

Source: In Journal of Thoracic Oncology December 2021 16(12):2040-2050

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Authors: Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C.H., Han, Ji-Youn, Hochmair, Maximilian J., Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander I., Gettinger, Scott N., Tiseo, Marcello, Lin, Huamao M., Liu, Yuyin, Vranceanu, Florin, Niu, Huifeng, Zhang, Pingkuan, Popat, Sanjay

Source: In Journal of Thoracic Oncology December 2021 16(12):2091-2108

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Authors: Byers, Lauren Averett, Navarro, Alejandro, Schaefer, Eric, Johnson, Melissa, Özgüroğlu, Mustafa, Han, Ji-Youn, Bondarenko, Igor, Cicin, Irfan, Dragnev, Konstantin H., Abel, Adam, Wang, Xuejing, McNeely, Samuel, Hynes, Scott, Lin, Aimee Bence, Forster, Martin

Source: In Clinical Lung Cancer November 2021 22(6):531-540

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

Authors: Jang, Seong Bok, Kim, Kyeong Bae, Sim, Sujin, Cho, Byoung Chul, Ahn, Myung-Ju, Han, Ji-Youn, Kim, Sang-We, Lee, Ki Hyeong, Cho, Eun Kyung, Haddish-Berhane, Nahor, Mehta, Jaydeep, Oh, Se-Woong

Source: In JTO Clinical and Research Reports October 2021 2(10)

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Authors: Herbst, Roy S., Garon, Edward B., Kim, Dong-Wan, Cho, Byoung Chul, Gervais, Radj, Perez-Gracia, Jose L., Han, Ji-Youn, Majem, Margarita, Forster, Martin D., Monnet, Isabelle, Novello, Silvia, Gubens, Matthew A., Boyer, Michael, Su, Wu-Chou, Samkari, Ayman, Jensen, Erin H., Kobie, Julie, Piperdi, Bilal, Baas, Paul

Source: In Journal of Thoracic Oncology October 2021 16(10):1718-1732

Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer

Authors: Lee, Youngjoo, Joo, Jungnam, Lee, You Jin, Lee, Eun Kyung, Park, Sohyun, Kim, Tae-Sung, Lee, Soo-Hyun, Kim, So Young, Wie, Gyung-Ah, Park, Minjoung, Kim, Mi-Jung, Lee, Jin Soo, Han, Ji-Youn ^*

Source: In Lung Cancer January 2021 151:8-15